Age and Comorbidities Influence Initial Treatment of Patients with Early Rheumatoid Arthritis

DAVID VEGA-MORALES, DANIEL TREVIÑO-MONTES and MARTIN WAH-SUAREZ

J Rheumatol 2016;43;827-828
http://www.jrheum.org/content/43/4/827

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Age and Comorbidities Influence Initial Treatment of Patients with Early Rheumatoid Arthritis

To the Editor:

We are quite interested in the study recently published by Dr. Helga Radner, et al1, in which they compared treatment profiles between multimorbidity established rheumatoid arthritis (RA) patients and patients with RA only. They found a decrease in biologic disease-modifying antirheumatic drugs used for each additional chronic comorbidity1. We, too, have observed the influence of comorbidities on decision making in the initial treatment of patients with early RA. The aim of our study was to evaluate such influences. Our retrospective and observational study was done between March 2014 and March 2015. We included all medical records of patients with RA according to 2010 American College of Rheumatology/European League Against Rheumatism classification criteria2. Then we selected only the first-time medical evaluation. We made a descriptive analysis for clinical and demographic variables, initial treatments, and compared the comorbidities. We found 101 patients with RA; 91 (90.1%) were female, with a mean age of 53.2 years (SD 12.7). Patients had a median of 12 months [interquartile range (IQR) 42] from the onset of symptoms to diagnosis. Sixty-seven patients (66.3%) had a positive rheumatoid factor (RF) and 32 (31.7%) had anti-citrullinated peptide antibodies (anti-CCP). There were 77 patients (76.2%) with at least 1 comorbidity. The most common comorbidities observed were diabetes mellitus in 16 patients (15.8%), systemic hypertension in 26 (25.7%), and hypothyroidism in 13 (12.9%). The median 28-joint Disease Activity Score (DAS28) using erythrocyte sedimentation rate (ESR) was 2.37 (IQR 2.01).

Table 1 shows the different combinations of treatments used. No patient had triple therapy at baseline. In bivariate analysis, we did not find a significance in RF or anti-CCP levels, time from the onset of symptoms to diagnosis, or DAS28 ESR as predictors of the use of methotrexate (MTX) alone or in combination in the initial treatment. We observed a median age of 59.5 years (IQR 21) in the patients who used only MTX, versus 52 years (IQR 17) in patients with MTX in combination (p = 0.028). The presence of at least 1 comorbidity was associated with the use of MTX alone [35% vs 12.5%, p = 0.027, OR 3.78 (95% CI 1.03-13.8)]. We did not observe the influence of other variables studied in the treatment decision.

We observed that the patient’s age and comorbidities influenced initial treatment of patients with early RA. The comorbidity in patients with RA affects morbidity-mortality, perhaps through the treatment choices. Previously, Dr. Radner, et al evaluated a systematic review how gastrointestinal and liver comorbidities influence the choice of pain treatment in inflammatory arthritis, including in patients with RA. Later, Listing, et al evaluated the increased risk of infections in patients with RA associated with the disease per se, the comorbidities, and its treatment4. Recently, Nakajima, et al found that comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with RA5. It is noteworthy that all studies have been conducted in patients with established RA, unlike our observation. The window of opportunity that has been described not only helps us to initiate timely treatment to avoid complications or sequelae of the disease6. It also allows evaluation of the comorbidities in a systematic way, to reduce morbidity and mortality.

REFERENCES


